Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antares Pharma, Inc.

http://www.antarespharma.com/

Latest From Antares Pharma, Inc.

Strides Says Forsteo Biosimilar ‘Significant Product’, Seeks New Minority Investor In Stelis

Strides sees Kauliv, a biosimilar to Eli Lilly’s Forsteo, as a ‘significant’ but ‘not a massive product’ as it prepares to register it in multiple countries post a positive opinion from EMA. Meanwhile, more clarity on fund raising for Stelis is expected by March 2023 even as the regulatory timeline for a COVID-19 vaccine from Akston is extended by 2-3 months

Commercial Business Strategies

Manufacturer Donations To Copay Charities: Profitability Underscores Kickback Concerns – Study

Department of Justice anti-kickback expert seeks to quantify the potential for manufacturers to benefit from donations to independent copay assistances organizations.

Reimbursement Compliance

Finance Watch: Third Harmonic Attempts A Flight Through The IPO Window

Public Company Edition: Third Harmonic hopes to double its money, raising up to $150m. Also, Halozyme priced a $625m note sale to retire debt and repurchase shares, while Viridian raised $270m in an offering after positive early data, and Clarus cut jobs while Endo finalized a restructuring plan.

Financing Business Strategies

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
      • Transdermal
  • Other Names / Subsidiaries
    • Halozyme Therapeutics, Inc.
    • Medi-Ject Corporation
    • Permatec
UsernamePublicRestriction

Register